PepsiCo CEO Ramon Laguarta said during an analyst call Tuesday that medications used for weight loss or diabetes have had a "negligible" influence on the company.
Nonetheless, he stated that the corporation is keeping an eye on them:
"We're observing the growth of these new drugs and its potential impact."
Some food analysts have warned that long-term use of semaglutide medications
like Ozempic and Wegovy, which act by lowering appetites, could significantly alter customer consumption habits.
They claim that food corporations must prepare for this possibility.
In 2023, around 1.7% of the American population was prescribed a semaglutide medication, a 40-fold increase over the previous five years.
Its popularity has already grown.